This is part 2 of an article where was interviewed for at Bio Similar Development. The article was discussing biosimilars and their impact on patients, oncologists, and healthcare system. This is critical as we are experiencing changes in reimbursement models and operational challenges for effective healthcare delivery.
Medscape Oncology Insights recently published an interview I conducted with Dr Jeff Sharman, director of research at Willamette Valley Cancer Institute and medical director of hematology research for The US Oncology Network.
As we kicked off 2020, one of the most anticipated events for the industry was the introduction of several more Herceptin, Avastin, and Rituxan competitors in the curative oncology mAb space. After the first three launches which will be completed in March, the U.S. will have finally welcomed a little more than half of the 26 biosimilars currently approved.
I recently led a discussion with Elias J. Jabbour, MD and S. Vincent Rajkumar, MD that was posted at Medscape.com.
This commentary was shared on Medscape and created quit a buzz! With over 330 comments, there was certainly a lot of interest in the topic.
I read this fascinating book “Chasing my Cure” written by the amazing David Fajgenbaum on his journey fighting Castleman Disease. Battling this disease has shaped David’s journey and forming the Castleman Disease Collaborative Network (CDCN). I then interviewed David on my “Outspoken Oncology” Podcast.
I recently shared my thoughts on Medscape on the importance of “Real World Evidence.”
Chadi Nabhan, MD MBA of Aptitude Health discusses the potential of biosimilars in the treatment of blood cancer.
Dr. Nabhan has been podcasting for years. His first podcast “Outspoken Oncology” started in February 2019 and won him two communication awards especially with dedicated coverage to COVID-19 when the pandemic started. That podcast retired in the summer of 2020 and Dr. Nabhan currently hosts two podcasts:
Healthcare Unfiltered: unedited and daring podcast tackling all aspects of healthcare hosting thought leaders from all over the world addressing timely and relevant debates that are important to everyone in the healthcare industry
HemOnc Pulse: Started in December 2022 and is dedicated to hematology and only hematology. Dr. Nabhan hosts thought leaders in the field of hematology discussing recent updates, new published research, debates, and asks questions that are essential to clinical care. This podcast is sponsored by Blood Cancers Today and SOHO.
